Table E1 Study entry criteria & diagnostic confidence of patients with ocular myasthenia gravis
Study entry criteria Diagnostic confidence
Inclusion criteria
1. Patients with probable or de�inite MG, diagnosed by clinical assessment, supported by additional investigations including ice- pack or edrophonium test, neurophysiology and serology 31:
•
Weakness of more than one extra-ocular muscle, eyelid levator and eye closure•
Variability of weakness•
FatigabilityDefinite OMG (i.e. supported by at least one abnormal diagnostic test)
Probable OMG*
(i.e. diagnostic tests negative)
•
At least one of the following abnormal diagnostic tests:o Elevated acetylcholine receptor antibody titers, o Abnormal repetitive nerve stimulation (>10%
decrement following slow repetitive nerve stimulation) of any nerve-muscle pair,
o Abnormal jitter on single �ibre or concentric needle electromyography in any muscle
o Positive ice test or positive edrophonium test
2. Patients with minimum follow up of 2 years from �irst onset of ocular symptoms
3. Duration of ocular symptoms only for minimum of 3 months from onset 5
4. Patients aged 17 years or older
Exclusion criteria
1. Incomplete information on symptoms or treatment received at onset of disease
2. Patients already on immunosuppression or corticosteroids for MG or another condition
3. Patients who have evidence of facial or limb weakness, or dysphagia or dyspnoea secondary to MG within 3 months of
�irst symptoms Note:
* One patient who had all diagnostic tests negative later developed generalised MG, and was therefore counted as 'definite MG' in the Results section of the manuscript.
Inclusion criteria in part adapted from (5) (33).
